Having received a unanimous vote of support from a US Food and DrugAdministration advisory committee for the launch of Natrecor (nesiritide) for the treatment of patients with acute congestive heart failure (see page 18), Scios says it is commencing a public offering of 5 million shares of common stock. The underwriters are JP Morgan, Lehman Brothers and SG Cowen, which will have the option to purchase up to an additional 750,000 shares to cover any overallotments. Scios' share price is currently around the $25 mark.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze